Full Press Release Details
Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody and
ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody
Posters presented at the 63rd American Society of Hematology Annual Meeting -
DIEGO and SUZHOU, China, December 13, 2021 - Adagene Inc. ("Adagene") (Nasdaq: ADAG), a biopharmaceutical
company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced preclinical data
demonstrating the compelling differentiation of ADG153, an anti-CD47 monoclonal antibody (mAb), and ADG152, a CD20xCD3 bispecific T-cell
engager (TCE). The data were presented in two poster presentations at the 63rd American Society of Hematology (ASH) Annual
Meeting & Exposition taking place December 11-14, 2021, which are available in the Publications section of the company's
website at www.adagene.com.
novel anti-CD47 antibody and CD20xCD3 bispecific TCE programs successfully leverage SAFEbody technology for precision masking to
decouple efficacy from the toxicities that are often associated with therapeutic modalities for these two important targets on the forefront
of clinical development for hematologic malignancies," said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of
Adagene. "Our preclinical evaluation shows the desirable target product profiles of these two transformative programs emerging from
our deep, broad and differentiated pipeline. In particular, we are very excited about our highly differentiated anti-CD47 SAFEbody in
IgG1 format, which introduces IgG1-mediated effects for potent tumor killing with a compelling safety profile and 8-fold prolonged half-life.
Our first POWERbody CD20xCD3 bispecific TCE with precision masking on our tailor-made anti-CD3 arm is highly differentiated, engineered
for potent and sustained tumor killing with more than 100-fold cytokine release control and 2-3-fold prolonged half-life in comparison
with a benchmarked antibody in clinical development. Together, these two programs highlight the strength of our AI-powered antibody platform,
paving the way for explosive growth of our pipeline."
ADG153 (Anti-CD47 SAFEbody)
Key findings from the poster (#3342) titled "ADG153, an Anti-CD-47
Monoclonal Antibody Prodrug, Has Strong In Vivo Anti-Tumor Activity, Minimal RBC-Related and Antigen Sink Liabilities, and Extended
Half Life in Comparison with Benchmark Clinical Antibodies of the Same IgG Subclass" include:
ADG152 (CD20xCD3 POWERbody)
findings from the poster (#1204) titled "ADG152, a Novel CD20xCD3 T-Cell Engager Prodrug with Enhanced Therapeutic Index,
Demonstrates Strong Anti-Tumor Activity with Improved Safety" include:
has been a longstanding challenge of T-cell engagers and has limited the ability to safely provide high levels of activity during initial
dosing," said Stanley Frankel, M.D., a clinical advisor who contributed to development and approval of blinatumomab
(Blincyto ) while working at Micromet and Amgen. "I am encouraged that the preclinical profile of ADG152 offers potential
to provide a way to simplify treatment by avoiding step dosing and pretreatment with steroids, while also enhancing efficacy of this POWERbody
to engage T-cells to attack tumor targets."
Both ADG153 and ADG152 are potential
Investigational New Drug candidates from Adagene's growing portfolio of preclinical discovery programs, five of which are in IND-enabling
studies. The preclinical data presented at ASH provide a strong rationale for advancing these potentially best-in-class candidates
into clinical development.
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical
company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational
biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision
Library (DPL) platform, composed of NEObody , SAFEbody , and POWERbody technologies, Adagene's highly
differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners
that leverage its technology in multiple approaches at the vanguard of science.
more information, please visit: https://investor.adagene.com.
is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Safe Harbor Statement
This press release contains forward-looking statements, including statements
regarding the potential implications of preclinical results, and Adagene's advancement of, and anticipated clinical activities,
clinical development and regulatory milestones of its product candidates. Actual results may differ materially from those indicated in
the forward-looking statements as a result of various important factors, including but not limited to Adagene's ability to demonstrate
the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development
or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval
of Adagene's drug candidates; Adagene's ability to achieve commercial success for its drug candidates, if approved; Adagene's
ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene's reliance on third parties
to conduct drug development, manufacturing and other services; Adagene's limited operating history and Adagene's ability to
obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene's
ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact
of the COVID-19 pandemic on Adagene's clinical development, commercial and other operations, as well as those risks more fully discussed
in the "Risk Factors" section in Adagene's filings with the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.